This book examines the role of pharmacogenomics in rheumatologic treatments. It covers genetic markers that predict responses to therapies for conditions like rheumatoid arthritis and lupus. The book emphasizes personalized treatment plans to enhance efficacy and reduce adverse effects in rheumatology patients. Targeted at rheumatologists and pharmacogenomic researchers, it promotes precision medicine in managing autoimmune diseases.
Nathan Brooks applies pharmacogenomics to rheumatology within dermatology, personalizing treatments for skin conditions associated with rheumatic diseases like lupus. His research explores how genetic variations affect responses to immunomodulatory therapies used in managing autoimmune-related skin disorders. Nathan has authored numerous studies on integrating pharmacogenomic testing into rheumatologic dermatological care to enhance treatment efficacy and reduce adverse effects. He also offers guidelines for clinicians to incorporate pharmacogenomic strategies into rheumatology-focused dermatological treatments, promoting personalized and effective care for patients with autoimmune skin conditions through genetic-informed approaches.